OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
Donovan McGrowder, Fabian Miller, Kurt Vaz, et al.
Brain Sciences (2021) Vol. 11, Iss. 2, pp. 215-215
Open Access | Times Cited: 105
Donovan McGrowder, Fabian Miller, Kurt Vaz, et al.
Brain Sciences (2021) Vol. 11, Iss. 2, pp. 215-215
Open Access | Times Cited: 105
Showing 51-75 of 105 citing articles:
Biomarkers of Activity-Dependent Plasticity and Persistent Enhancement of Synaptic Transmission in Alzheimer Disease: A Review of the Current Status
Marcin Warpechowski, Jędrzej Warpechowski, Agnieszka Kulczynska‐Przybik, et al.
Medical Science Monitor (2022) Vol. 29
Open Access | Times Cited: 8
Marcin Warpechowski, Jędrzej Warpechowski, Agnieszka Kulczynska‐Przybik, et al.
Medical Science Monitor (2022) Vol. 29
Open Access | Times Cited: 8
Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder
Stefan Teipel, Davide Bruno, Chelsea Reichert Plaska, et al.
Journal of Affective Disorders (2021) Vol. 293, pp. 429-434
Open Access | Times Cited: 11
Stefan Teipel, Davide Bruno, Chelsea Reichert Plaska, et al.
Journal of Affective Disorders (2021) Vol. 293, pp. 429-434
Open Access | Times Cited: 11
Proteomics As A Valid Tool In Biomarker Discovery For Alzheimer's Disease
Valeria Magnelli
(2024)
Open Access | Times Cited: 1
Valeria Magnelli
(2024)
Open Access | Times Cited: 1
The Relationship between SNAP25 and Some Common Human Neurological Syndromes
Jie Shu, Fan Peng, Jing Li, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 30, pp. 2378-2386
Closed Access | Times Cited: 1
Jie Shu, Fan Peng, Jing Li, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 30, pp. 2378-2386
Closed Access | Times Cited: 1
Polygenic hazard score profile is an effective genetic predictor of synaptic and axonal degeneration and cognitive decline in Alzheimer's disease spectrum
Mohammad‐Erfan Farhadieh, Mehrdad Mozafar, Saameh Sanaaee, et al.
Archives of Gerontology and Geriatrics (2024) Vol. 127, pp. 105576-105576
Closed Access | Times Cited: 1
Mohammad‐Erfan Farhadieh, Mehrdad Mozafar, Saameh Sanaaee, et al.
Archives of Gerontology and Geriatrics (2024) Vol. 127, pp. 105576-105576
Closed Access | Times Cited: 1
Research progress on humoral biomarkers of Alzheimer’s disease: A review
Hao Zhang, Xiaofeng Fu, Mengyu Yang, et al.
Medicine (2024) Vol. 103, Iss. 30, pp. e38978-e38978
Open Access | Times Cited: 1
Hao Zhang, Xiaofeng Fu, Mengyu Yang, et al.
Medicine (2024) Vol. 103, Iss. 30, pp. e38978-e38978
Open Access | Times Cited: 1
Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: an update of the literature
Tina Milos, Barbara Vuić, N. Balic, et al.
Expert Review of Neurotherapeutics (2024), pp. 1-17
Closed Access | Times Cited: 1
Tina Milos, Barbara Vuić, N. Balic, et al.
Expert Review of Neurotherapeutics (2024), pp. 1-17
Closed Access | Times Cited: 1
Combining Biomarkers with Genetics In Prodromal/Earliest Phase Parkinson’s Disease
Philip Seibler, Linn Streubel-Gallasch, Christine Klein
Journal of Parkinson s Disease (2024), pp. 1-7
Open Access | Times Cited: 1
Philip Seibler, Linn Streubel-Gallasch, Christine Klein
Journal of Parkinson s Disease (2024), pp. 1-7
Open Access | Times Cited: 1
Altered Blood Levels of Anti-Gal Antibodies in Alzheimer’s Disease: A New Clue to Pathogenesis?
Antonella Angiolillo, Alessandro Gandaglia, Alessia Arcaro, et al.
Life (2021) Vol. 11, Iss. 6, pp. 538-538
Open Access | Times Cited: 10
Antonella Angiolillo, Alessandro Gandaglia, Alessia Arcaro, et al.
Life (2021) Vol. 11, Iss. 6, pp. 538-538
Open Access | Times Cited: 10
Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
Ioanna Tsantzali, Aikaterini Foska, Eleni Sideri, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1879-1879
Open Access | Times Cited: 7
Ioanna Tsantzali, Aikaterini Foska, Eleni Sideri, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1879-1879
Open Access | Times Cited: 7
Biological Significance of the Protein Changes Occurring in the Cerebrospinal Fluid of Alzheimer’s Disease Patients: Getting Clues from Proteomic Studies
Cristina M. Pedrero-Prieto, Javier Frontiñán-Rubio, Francisco J. Alcaı́n, et al.
Diagnostics (2021) Vol. 11, Iss. 9, pp. 1655-1655
Open Access | Times Cited: 9
Cristina M. Pedrero-Prieto, Javier Frontiñán-Rubio, Francisco J. Alcaı́n, et al.
Diagnostics (2021) Vol. 11, Iss. 9, pp. 1655-1655
Open Access | Times Cited: 9
Plasma P-Tau181 for the Discrimination of Alzheimer’s Disease from Other Primary Dementing and/or Movement Disorders
John S. Tzartos, Fotini Boufidou, Christos Stergiou, et al.
Biomolecules (2022) Vol. 12, Iss. 8, pp. 1099-1099
Open Access | Times Cited: 6
John S. Tzartos, Fotini Boufidou, Christos Stergiou, et al.
Biomolecules (2022) Vol. 12, Iss. 8, pp. 1099-1099
Open Access | Times Cited: 6
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer’s disease
Lorenzo Gaetani, Davide Chiasserini, Federico Paolini Paoletti, et al.
Expert Review of Molecular Diagnostics (2023) Vol. 23, Iss. 12, pp. 1195-1207
Closed Access | Times Cited: 3
Lorenzo Gaetani, Davide Chiasserini, Federico Paolini Paoletti, et al.
Expert Review of Molecular Diagnostics (2023) Vol. 23, Iss. 12, pp. 1195-1207
Closed Access | Times Cited: 3
The Biochemistry Behind Cognitive Decline: Biomarkers of Alzheimer's Disease.
Oussama Grari, Dounia Elmoujtahide, El-houcine Sebbar, et al.
PubMed (2023) Vol. 34, Iss. 4, pp. 276-283
Closed Access | Times Cited: 3
Oussama Grari, Dounia Elmoujtahide, El-houcine Sebbar, et al.
PubMed (2023) Vol. 34, Iss. 4, pp. 276-283
Closed Access | Times Cited: 3
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
George P. Paraskevas, Elisabeth Kapaki
Brain Sciences (2021) Vol. 11, Iss. 10, pp. 1258-1258
Open Access | Times Cited: 8
George P. Paraskevas, Elisabeth Kapaki
Brain Sciences (2021) Vol. 11, Iss. 10, pp. 1258-1258
Open Access | Times Cited: 8
Neuroproteomics Chip-Based Mass Spectrometry and Other Techniques for Alzheimer’s Disease Biomarkers – Update
Alicia B. Pomilio, Arturo A. Vitale, Alberto Lazarowski
Current Pharmaceutical Design (2022) Vol. 28, Iss. 14, pp. 1124-1151
Closed Access | Times Cited: 5
Alicia B. Pomilio, Arturo A. Vitale, Alberto Lazarowski
Current Pharmaceutical Design (2022) Vol. 28, Iss. 14, pp. 1124-1151
Closed Access | Times Cited: 5
Cerebrospinal fluid markers of inflammation and brain injury in Lyme neuroborreliosis – a prospective follow-up study
Ivar Tjernberg, Paula Gyllemark, Henrik Zetterberg, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2022) Vol. 60, Iss. 7, pp. 1124-1132
Open Access | Times Cited: 5
Ivar Tjernberg, Paula Gyllemark, Henrik Zetterberg, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2022) Vol. 60, Iss. 7, pp. 1124-1132
Open Access | Times Cited: 5
Entropy and Fractal Analysis of EEG Signals for Early Detection of Alzheimer's Dementia
Sugondo Hadiyoso, Inung Wijayanto, Annisa Humairani
Traitement du signal (2023) Vol. 40, Iss. 04, pp. 1673-1679
Open Access | Times Cited: 2
Sugondo Hadiyoso, Inung Wijayanto, Annisa Humairani
Traitement du signal (2023) Vol. 40, Iss. 04, pp. 1673-1679
Open Access | Times Cited: 2
Can Genetic Markers Predict the Sporadic Form of Alzheimer’s Disease? An Updated Review on Genetic Peripheral Markers
D. Theron, Lloyd N. Hopkins, Heidi G. Sutherland, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13480-13480
Open Access | Times Cited: 2
D. Theron, Lloyd N. Hopkins, Heidi G. Sutherland, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13480-13480
Open Access | Times Cited: 2
Bibliometric review on biomarkers for Alzheimer’s disease between 2000 and 2023
Xiaojie Yang, Huiling Qu
Medicine (2023) Vol. 102, Iss. 36, pp. e34982-e34982
Open Access | Times Cited: 2
Xiaojie Yang, Huiling Qu
Medicine (2023) Vol. 102, Iss. 36, pp. e34982-e34982
Open Access | Times Cited: 2
The Role of Cerebrospinal Fluid Biomarkers in Dementia and Other Related Neurodegenerative Disorders
George P. Paraskevas
Brain Sciences (2022) Vol. 12, Iss. 5, pp. 627-627
Open Access | Times Cited: 3
George P. Paraskevas
Brain Sciences (2022) Vol. 12, Iss. 5, pp. 627-627
Open Access | Times Cited: 3
From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer’s Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients
Ioanna Tsantzali, Fotini Boufidou, Eleni Sideri, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1376-1376
Open Access | Times Cited: 4
Ioanna Tsantzali, Fotini Boufidou, Eleni Sideri, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1376-1376
Open Access | Times Cited: 4
Evaluation of the biodistribution and preliminary safety profile of a novel brain-targeted manganese dioxide-based nanotheranostic system for Alzheimer’s disease
Lily Yi Li, Elliya Park, Chunsheng He, et al.
Nanotoxicology (2024) Vol. 18, Iss. 4, pp. 315-334
Closed Access
Lily Yi Li, Elliya Park, Chunsheng He, et al.
Nanotoxicology (2024) Vol. 18, Iss. 4, pp. 315-334
Closed Access
The identification of biomarkers for Alzheimer's disease using a systems biology approach based on lncRNA-circRNA-miRNA-mRNA ceRNA networks
Babak Sokouti
Computers in Biology and Medicine (2024) Vol. 179, pp. 108860-108860
Closed Access
Babak Sokouti
Computers in Biology and Medicine (2024) Vol. 179, pp. 108860-108860
Closed Access
